Peptides for Eye Health Research – Complete Guide

Table of Contents

• Eye Health Research Snapshot
• Eye Health Research Landscape Overview
• How Peptides Are Being Studied for Eye Health
• Major Eye Health Peptides Under Investigation
• Eye Health Study Models and Research Volume
• Eye Health Clinical Pipeline and Trial Status
• Eye Health Research Limitations and Evidence Gaps
• Regulatory and Research Classification
• Frequently Asked Questions About Eye Health Peptide Research
• References

Eye Health Research Snapshot

Peptides Under Investigation	12 or more major peptides and peptide classes with published research across preclinical and early clinical stages
Research Maturity	Predominantly preclinical: most compounds limited to animal models and cell culture; GLP-1 receptor agonists have retrospective human cohort data; ST-100 reached Phase 3 trials for dry eye disease
Most Studied Peptides	PEDF-derived peptides (H105A, 17-mer) and elamipretide by preclinical publication depth; ST-100 (vezocolmitide) by clinical trial advancement; GLP-1 receptor agonists by human cohort volume
Primary Mechanisms Studied	Photoreceptor neuroprotection via PEDF signaling, VEGF suppression to reduce abnormal vessel growth, mitochondrial protection in retinal cells, collagen matrix repair in the cornea, and inflammatory pathway modulation at multiple targets
Clinical Trial Status	ST-100 completed Phase 2 and Phase 3 trials for dry eye disease with mixed results; GLP-1 receptor agonists studied in retrospective cohorts but no completed RCTs for eye-specific indications; CG-P5 peptide eye drops in Phase 1 safety evaluation; all other peptides remain preclinical
Regulatory Classification	Research use only for all peptides discussed; no peptide specifically indicated for any eye condition has received FDA approval
WADA Status	GLP-1 receptor agonists are not currently on the WADA Prohibited List; elamipretide and PEDF-derived peptides are not listed; researchers should verify current WADA classification against the most recent published list

Eye Health Research Landscape Overview

The eye presents one of the most challenging environments in medicine for drug delivery and one of the most urgent frontiers for new therapeutic approaches. Age-related macular degeneration affects more than 196 million people globally and is the leading cause of irreversible vision loss in adults over 50. Retinitis pigmentosa, a group of inherited retinal degenerations, affects approximately 1 in 4,000 people worldwide and currently has no broadly effective treatment that halts photoreceptor loss. Dry eye disease affects hundreds of millions of people globally, and diabetic retinopathy threatens the vision of approximately one-third of all people living with diabetes. These conditions share a common problem: the biological processes driving vision loss are well understood at the molecular level, but existing drugs struggle to reach the right tissues at the right concentrations, or they address only part of a complex, multi-pathway disease process. peptide research has emerged as a serious response to both of these challenges. Short peptides can be designed to engage specific protein-protein interactions and receptor systems with high precision, targeting biological events that conventional small-molecule drugs cannot easily reach. Equally important, peptides can be engineered into self-assembling formulations that form gel depots inside the eye for sustained drug release, conjugated to cell-penetrating carriers that move across the tough tissue barriers separating the eye’s outer surface from its light-sensitive interior, or formulated as topical drops that penetrate to the retina within an hour of application. Researchers have identified more than a dozen mechanistically distinct peptide approaches for eye health applications. These span conditions from the front of the eye, including dry eye disease, corneal damage, and ocular infections, to the deep interior, including photoreceptor degeneration, retinal neovascularization, optic nerve damage, and age-related mitochondrial decline in cone cells. The research field ranges from long-established endogenous neuropeptides like vasoactive intestinal peptide to entirely synthetic designer compounds like AXT107. It also includes the PEDF-derived fragments H105A and the 17-mer, each engineered to replicate or enhance the protective activities of naturally occurring retinal proteins. The overall research maturity is best described as early-to-intermediate, with considerable promise and significant gaps. One compound, ST-100 (vezocolmitide), has reached Phase 3 trials for dry eye disease with mixed results. GLP-1 receptor agonists, peptide-based drugs originally developed for type 2 diabetes, have generated a substantial body of human observational data showing associations with reduced rates of glaucoma, dry eye, and certain forms of retinal disease. No randomized controlled trial has been completed specifically for any eye indication. For the majority of peptides in this research landscape, human data does not yet exist, and the path from promising animal model findings to validated human treatments remains long and uncertain.

How Peptides Are Being Studied for Eye Health

Photoreceptor Neuroprotection

The retina contains roughly 120 million rod photoreceptors, responsible for vision in low light, and 6 million cone photoreceptors, responsible for color and fine detail vision. In diseases like retinitis pigmentosa and age-related macular degeneration, these cells progressively die, often because the biological signals that normally keep them alive become disrupted or overwhelmed by stress. Pigment epithelium-derived factor (PEDF) is a naturally occurring protein in the eye that plays a central role in keeping photoreceptors alive. It does this by binding receptors on photoreceptor cell surfaces and triggering a series of protective signals inside the cell that block the programmed cell death process. Researchers have isolated short peptide fragments from the PEDF protein, including H105A and the 17-mer, that retain these neuroprotective signals in a form small enough to penetrate the eye from topically applied drops. In mouse models of retinitis pigmentosa, these fragments reach the retina within 60 minutes of application and slow photoreceptor loss by up to 75% compared to untreated animals [1]. The connection to age-related macular degeneration is also under active investigation because PEDF levels in the eye naturally decline with aging, and restoring PEDF-like signaling through peptide fragments is a pharmacologically rational approach to counteracting this decline [1].

VEGF Suppression and Sustained Ocular Drug Delivery

Vascular endothelial growth factor (VEGF) is a signaling protein that normally helps blood vessels grow and repair themselves. In several serious eye diseases, including wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, VEGF is overproduced, driving the growth of fragile, leaky blood vessels in and around the retina that damage photoreceptors and cause vision loss. The current standard of care involves monthly or bimonthly injections of anti-VEGF drugs directly into the vitreous fluid of the eye, a procedure that is effective but burdensome and associated with compliance challenges. Peptide researchers are pursuing two distinct approaches to this problem. The first is designing synthetic peptides that suppress VEGF-driven vessel growth more potently and durably than existing drugs. AXT107 exemplifies this approach: it forms a self-assembling gel inside the eye after injection and releases its anti-VEGF activity over a longer period than conventional monthly injections [2]. The second is using cell-penetrating peptides to carry existing anti-VEGF biologics into the posterior eye through topical eye drops rather than injections, exemplified by the bxyPenetratin system for delivering aflibercept [6].

Mitochondrial Protection in the Aging Retina

Photoreceptors are among the most metabolically demanding cells in the human body. Cones, the photoreceptors responsible for daytime and color vision, rely heavily on mitochondria, the energy-generating structures inside cells, to power their continuous light-sensing activity. As the eye ages, mitochondria in cone cells accumulate damage, produce less energy, and generate harmful byproducts called reactive oxygen species that damage the cell from within. Elamipretide (also called SS31) is a four-amino acid peptide that specifically targets a molecule called cardiolipin, which sits in the inner membrane of mitochondria and is critical for organizing the protein complexes that generate cellular energy. By binding cardiolipin, elamipretide stabilizes these energy-generating complexes and reduces the production of reactive oxygen species. In aged mice, daily elamipretide treatment preserved cone-mediated visual function with only 6% decline over six months, compared to a 16% decline in untreated animals over the same period, and treatment started in older animals reversed established acuity losses within two months [11]. This mechanism addresses one of the central drivers of age-related visual decline at a biological level that existing therapies do not reach.

Ocular Surface Inflammation and Collagen Repair

The front surface of the eye, including the cornea and conjunctiva, is constantly exposed to environmental stressors and depends on a healthy tear film and an intact structural matrix of collagen proteins to maintain clarity and comfort. In dry eye disease, this system breaks down through a cycle of surface inflammation, collagen matrix degradation by enzymes called matrix metalloproteinases, nerve damage, and reduced tear production that each worsen the others. ST-100 (vezocolmitide) is a collagen mimetic peptide designed to insert directly into damaged collagen structures in the cornea, restoring the normally organized triple-helical arrangement that gives healthy corneal collagen its strength and transparency. This structural repair approach is mechanistically distinct from any existing dry eye treatment and addresses corneal damage rather than just tear quantity. In a Phase 2 clinical trial in 160 patients, ST-100 met its primary endpoint of meaningfully increased tear production within 28 days [4]. Additional peptide approaches to ocular surface health include vasoactive intestinal peptide, an endogenous neuropeptide that stimulates the lacrimal glands to produce tears and suppresses ocular surface inflammation through immunomodulatory mechanisms [5].

Major Eye Health Peptides Under Investigation

This section covers twelve peptides and peptide classes with published evidence for eye health research applications. Compounds appear in order from most to least evidence-supported. The range of conditions covered spans retinal degeneration, age-related vision loss, dry eye disease, ocular neovascularization, and ocular surface infection.

PEDF-Derived Peptides (H105A and 17-mer)

PEDF-derived peptides are short fragments engineered from pigment epithelium-derived factor, a naturally occurring protein found throughout the human eye that plays a critical role in keeping photoreceptor cells alive. The two most studied variants are H105A, a 17-amino acid fragment, and the 17-mer, a related sequence from the same PEDF protein region. Both are small enough to penetrate the eye from topically applied drops, which is pharmacologically significant because delivering drugs to the retina without injection is one of the central unsolved challenges in ophthalmology. In mouse models of retinitis pigmentosa, daily H105A eye drop treatment slowed photoreceptor loss by up to 75% compared to untreated animals and preserved measurable retinal light responses. The peptide reached the retina within 60 minutes of topical application and showed no toxicity at tested concentrations [1]. These findings represent a significant proof-of-concept for non-invasive retinal drug delivery. The 17-mer variant demonstrated complementary activity in human retinal organoids, three-dimensional tissue models grown from human stem cells that closely replicate the layered structure of an actual retina. When these organoids were exposed to cigarette smoke extract and other chemical stressors that damage retinal cells, 17-mer treatment protected against cell death and maintained tissue architecture [1]. The biological rationale for both peptides connects directly to a well-characterized deficit: PEDF levels in the human eye decline with normal aging, and this decline correlates with increased photoreceptor vulnerability in both retinitis pigmentosa and age-related macular degeneration. Restoring PEDF-like signaling through small topical peptide fragments is therefore a pharmacologically grounded approach rather than a speculative one. No human clinical trial data exist for H105A or the 17-mer as of current available evidence. Both PEDF-derived peptide fragments are available as research compounds.

ST-100 (Vezocolmitide)

ST-100, also known by its development name vezocolmitide, is a collagen mimetic peptide formulated as topical eye drops for dry eye disease treatment. Dry eye disease involves not just a reduction in tear quantity but also progressive damage to the collagen matrix of the cornea, driven by enzymes called matrix metalloproteinases that break down the organized triple-helical collagen structure that gives the corneal surface its integrity. ST-100 is designed to insert into this damaged collagen structure and restore its organized geometry, an approach that is structurally different from any approved dry eye treatment. ST-100 advanced through a Phase 2 randomized controlled trial (NCT05241470) enrolling 160 patients across arms receiving twice-daily drops at concentrations of 20 mg/mL or 50 mg/mL compared to placebo. The trial met its primary endpoint: the Schirmer responder endpoint, which measures a meaningful increase in tear production of at least 10 millimeters on the standardized Schirmer test, was achieved within 28 days of treatment. Participants in the ST-100 arms also showed improvements in corneal staining scores, which measure surface cell damage, and patient-reported discomfort relative to placebo. No serious adverse events were reported in the Phase 2 study [4]. The Phase 3 trial subsequently produced mixed results, with outcomes that were more complicated than the Phase 2 signal suggested [4]. The reasons for the mixed Phase 3 data have not been fully characterized in the available literature, illustrating the common difficulty of replicating positive Phase 2 findings at larger scale in dry eye research, where placebo response rates are high and endpoint definitions are contested. ST-100 is available as a research compound for laboratory investigation.

GLP-1 Receptor Agonists

GLP-1 receptor agonists are a class of peptide-based drugs originally developed for type 2 diabetes management. They include compounds like exenatide, lg, GLP1, and lixisenatide. The connection to eye health emerged from observational data showing that diabetic patients treated with GLP-1 receptor agonists experienced lower rates of several eye conditions compared to diabetic patients on other medications. GLP-1 receptors are expressed not only in the pancreas but throughout the brain and eye, including in retinal cells and optic nerve tissue, providing a biological basis for direct ocular effects beyond those explained by blood sugar control alone. GLP-1 receptor activation in ocular tissues triggers protective signals inside the cell that reduce oxidative stress and inflammation in retinal and optic nerve cells. This signaling chain suppresses the same damaging processes that drive retinal cell loss in diabetic eye disease. A retrospective cohort study of 6,021 patients with type 2 diabetes found that GLP-1 receptor agonist users had significantly lower rates of dry eye disease and superficial keratitis compared to patients on other antidiabetic agents [3]. A 2024 cohort study published in JAMA Network Open found that GLP-1 receptor agonist use was associated with a 24% reduced risk of blindness, including a 30% reduced risk in patients who already had diabetic retinopathy [3]. A 2025 systematic review and meta-analysis pooling multiple studies found no significant overall association between GLP-1 receptor agonist use and diabetic retinopathy development or worsening after excluding studies with high bias risk, though randomized controlled trials showed a non-significant trend toward reduced risk [3]. The picture for diabetic retinopathy is more complex than other eye conditions. The same JAMA Network Open data showed a small increase in incident diabetic retinopathy in the first two years of GLP-1 receptor agonist use, likely reflecting rapid improvement in blood sugar control that can temporarily worsen retinal vessels before longer-term protection sets in. Topical ocular formulations of GLP-1 compounds are under preclinical investigation for dry eye disease, with liraglutide eye drops improving tear secretion and reducing inflammation in desiccating stress mouse models. All GLP-1 receptor agonist findings in this context come from observational studies or preclinical experiments: no randomized controlled trial has been completed with an eye health primary endpoint.

Elamipretide (SS31)

Elamipretide is a four-amino acid peptide designed to specifically target cardiolipin, a lipid molecule found exclusively in the inner membrane of mitochondria. Cardiolipin plays a structural organizing role for the protein complexes that generate ATP, the cell’s primary energy currency. When cardiolipin is damaged or reduced, these protein complexes fall apart, energy production drops, and harmful reactive oxygen species accumulate inside the cell. In photoreceptors, which require enormous amounts of continuous energy to power light sensing, this mitochondrial deterioration is a central driver of age-related visual decline. Elamipretide’s preclinical evidence for eye health comes from a series of longitudinal experiments in aged mice that carefully tracked visual function over time. When treatment began at 18 months of mouse age, elamipretide preserved photopic (daytime, color vision) visual function across the subsequent six-month observation period. Treated animals showed only 6% functional decline compared to 16% in untreated controls. When treatment began at 24 or 32 months of age, after acuity loss had already been established, elamipretide reversed the decline within approximately two months, and improvements persisted after treatment stopped [11]. The protection was specific to cone-mediated, photopic visual function. Rod-mediated scotopic (low-light vision) function was not significantly affected, suggesting that elamipretide’s mechanism is most relevant to the cone-rich central retina that drives the sharp, detailed, and color vision most important to daily life. Human clinical trial data for elamipretide in eye health specifically are limited in the available literature. The compound is available as a research compound and has been studied for other mitochondrial disease indications. Research into its ocular applications remains at the preclinical stage.

AXT107

AXT107 is a synthetic peptide engineered to suppress the abnormal blood vessel growth that damages the retina in wet age-related macular degeneration and diabetic macular edema. Its defining pharmacological feature is the ability to self-assemble into a stable gel depot inside the eye’s vitreous fluid after injection. This depot then releases AXT107 slowly over an extended period, potentially reducing the injection frequency that currently burdens patients undergoing monthly anti-VEGF treatments. In mouse models of retinal neovascularization, AXT107 outperformed aflibercept, one of the most widely used current anti-VEGF treatments, in suppressing abnormal vessel growth and promoting regression of vessels that had already formed [2]. The self-assembling depot mechanism is particularly important: standard anti-VEGF drugs dissipate within weeks of injection, which is why monthly re-injection is required, but a gel depot that releases drug continuously could maintain therapeutic levels over a much longer interval. The preclinical data were published in 2017 and have generated ongoing research interest in the self-assembling peptide depot approach as a platform relevant beyond AXT107 itself. No human clinical trial data for AXT107 were identified in the available evidence. AXT107 is available as a research compound.

Peptide Hydrogels for Wet AMD

Peptide hydrogels represent a research approach where the peptide itself forms the drug delivery system rather than being the therapeutic agent alone. In wet age-related macular degeneration models, researchers studied both pro-angiogenic and anti-angiogenic peptide hydrogel formulations delivered into a rat model of laser-induced choroidal neovascularization, which is the standard preclinical model for wet AMD. Both hydrogel types reduced vascular leakage to levels comparable to aflibercept over a 14-day observation window [7,8]. An unexpected finding from this research was that the pro-angiogenic hydrogel also reduced vascular leak in the short term. This suggests that the depot structure of the hydrogel itself may have physical effects on vascular behavior independent of the specific peptide cargo. This observation complicates interpretation of the results and points to the need for longer-term experiments and mechanistic dissection to understand what is driving the benefit. Sample sizes in these experiments were six to eight rats per group, which is typical for preliminary preclinical work but insufficient to draw strong conclusions about efficacy or durability. No human trial data exist for this approach.

Fas-Blocking Peptides (6R-FBP)

Fas-blocking peptides target a specific cell death pathway called Fas-mediated apoptosis. Apoptosis is the orderly, programmed process by which cells self-destruct when they are damaged or stressed. In the aging retina, Fas receptor signaling is chronically elevated and drives photoreceptor and retinal neuron death at a rate that exceeds the eye’s capacity for repair. The Fas-blocking peptide 6R-FBP combines a molecular blocker of the Fas death signal with six arginine amino acids that act as a cell-penetrating carrier, allowing the therapeutic payload to enter retinal cells after topical or intravitreal administration. In both rodent and rabbit models of age-related retinal degeneration, 6R-FBP treatment attenuated retinal degeneration as measured by retinal thickness measurements and reduced programmed cell death in photoreceptor layers [9]. The compound was studied by both eye drop and intravitreal injection routes, with both showing activity in the animal models. These findings position Fas-blocking peptides as a mechanistically distinct approach from VEGF-targeted or neuroprotection-targeted peptides, targeting the cell death execution machinery directly rather than the upstream signals that stress photoreceptors. All findings are from animal models. No human data are available. Research peptide variants of 6R-FBP are available for laboratory investigation.

Cell-Penetrating Peptides (TAT-μCL)

Cell-penetrating peptides function primarily as delivery vehicles rather than direct therapeutics. The TAT peptide sequence, derived from the HIV-1 transactivator protein, has the unusual ability to cross cell membranes that would normally block large molecules. When conjugated to therapeutic cargoes, TAT and related cell-penetrating sequences can transport drugs into cells and across the biological barriers that separate the ocular surface from the interior of the eye. In rat topical administration experiments, TAT-μCL applied to the ocular surface distributed to both the anterior segment (the front of the eye, including the cornea and lens) and the posterior segment (the back of the eye, including the retina), demonstrating that cell-penetrating peptide conjugation is a viable strategy for non-invasive delivery to deep ocular tissues [10]. When conjugated to anti-VEGF cargo molecules in wet AMD and diabetic macular edema models, CPP conjugation enhanced delivery to the posterior segment compared to unconjugated drug. This research addresses one of the fundamental barriers in ocular pharmacology: the difficulty of getting drugs to the retina without injecting them directly into the eye. Cell-penetrating peptides of several types are available as research compounds.

Peptide-Bound Aflibercept (bxyPenetratin)

bxyPenetratin (also designated bxyWP) represents a specific application of the cell-penetrating peptide delivery strategy applied to aflibercept, one of the most widely used anti-VEGF biologics in ophthalmology. Aflibercept is a large protein, approximately 115 kilodaltons, far too large to cross the ocular tissue barriers and reach the retina from topically applied drops under normal circumstances. The bxyPenetratin system uses a non-covalent binding interaction to attach the cell-penetrating peptide to aflibercept, forming a complex that retains anti-VEGF activity while gaining the ability to penetrate corneal and posterior segment tissues. Preclinical experiments published in 2024 in the journal Advanced Science demonstrated that the bxyPenetratin-aflibercept complex successfully delivered therapeutic concentrations of aflibercept to posterior eye tissues after topical application in animal models [6]. The significance of this finding extends beyond aflibercept specifically: if a peptide carrier system can deliver a protein of aflibercept’s size to the retina through eye drops, the same principle could potentially be applied to other large therapeutic proteins that are currently restricted to injection-only delivery. The research remains at the preclinical formulation stage. No human data are available for this delivery system.

Vasoactive Intestinal Peptide (VIP)

Vasoactive intestinal peptide is a 28-amino acid neuropeptide naturally produced throughout the nervous system. In the context of eye health, VIP research focuses on dry eye disease, where the peptide acts on multiple fronts simultaneously: stimulating the lacrimal glands to produce tears, promoting mucin secretion from conjunctival goblet cells that makes up part of the protective tear film, and reducing inflammatory activity on the ocular surface through immunomodulatory signaling. Current VIP research for eye health is at an early observational stage. A pilot study in COVID-19 survivors, a population that showed elevated rates of dry eye disease following infection, investigated the effects of proton pump inhibitors (medications that elevate endogenous VIP levels) on dry eye symptoms [5]. The study found reduced dry eye rates in proton pump inhibitor users compared to patients taking other gastrointestinal medications. The study authors proposed that the VIP-elevating effect of these medications may have contributed to ocular surface protection and called for dedicated clinical trials of topical VIP formulations for dry eye disease [5]. No such trials were identified in the available literature. Synthetic VIP is available as a research compound.

ALG-1001 (Integrin Peptide)

ALG-1001 is a synthetic oligopeptide that targets integrin receptors on cell surfaces. Integrins are proteins embedded in cell membranes that act as anchors, connecting the inside of the cell to the surrounding structural matrix and to other cells. In the context of eye disease, specific integrin receptor pairs play important roles in both the abnormal blood vessel growth of vascular retinal disease and the pathological attachment of the vitreous gel to the retinal surface in conditions like vitreomacular adhesion and diabetic macular edema. ALG-1001 targets multiple integrin subtypes simultaneously, disrupting the cell-matrix signaling that drives abnormal vessel growth while also releasing vitreoretinal adhesions by displacing the vitreous from the retinal surface. Animal model data established the mechanism. Human trial data demonstrated that ALG-1001 could induce posterior vitreous detachment (the separation of the vitreous gel from the retinal surface, confirmed by ultrasound imaging) in clinical study participants [12,13]. This makes ALG-1001 notable as one of the few peptides in eye health research to have generated direct human evidence of a measurable biological effect, even though the full clinical evidence base and trial phase details are not comprehensively documented in available sources. Research is ongoing.

Host-Defense Peptides (hBD-2, hBD-3, LL-37)

Host-defense peptides, also called antimicrobial peptides, are part of the eye’s natural immune defense at the ocular surface. Human beta-defensins 2 and 3 (hBD-2 and hBD-3) and the cathelicidin LL-37 are found naturally in human tears and secretions from the conjunctiva and cornea. Research into these peptides for eye health focuses on understanding and potentially augmenting the eye’s intrinsic antimicrobial defenses against bacterial keratitis and other ocular surface infections. hBD-2 and hBD-3 kill bacteria by exploiting the electrical charge difference between microbial and human cell membranes. Bacterial membranes carry a net negative charge, while human cell membranes are largely neutral. The defensins, which carry positive charges, are drawn to bacterial membranes and disrupt their integrity, causing bacterial death, while human cells remain largely unaffected. LL-37 adds another mechanism: it binds lipopolysaccharide, a component found on the outer surface of gram-negative bacteria, and blocks the excessive inflammatory response that this bacterial product normally triggers. This dual action, both killing bacteria directly and dampening the inflammation that bacterial products provoke, makes LL-37 of interest not just as an antimicrobial but as an inflammation regulator on the ocular surface. Current research on these peptides is primarily mechanistic, documenting their natural activity rather than testing them as administered therapeutics.

TLR-Inhibiting Peptides for Dry AMD

TLR-inhibiting peptides represent one of the most recently reported approaches in eye health peptide research. Toll-like receptors (TLRs) are part of the immune system’s alarm network, triggering inflammation when they detect molecular patterns associated with infection or tissue damage. In dry age-related macular degeneration, chronic low-grade TLR activation drives the progressive loss of retinal pigment epithelium (the cell layer that supports and nourishes photoreceptors) and the accumulation of drusen deposits under the retina that are the hallmark of the disease. Researchers conducted a high-throughput screen of more than 190,000 peptide candidates and identified lead compounds capable of inhibiting TLR inflammatory signaling in retinal tissues [14,15]. In mouse models of dry AMD, these peptides delivered as eye drops reduced drusen accumulation, retinal pigment epithelium loss, and overall retinal degeneration. The findings were reported in December 2024, making this one of the most recently published peptide approaches for eye health covered in this article [14,15]. All evidence is from animal models. No human trial data exist. The research represents a novel mechanistic direction for dry AMD, a condition with very few effective treatment options.

Eye Health Study Models and Research Volume

Eye health peptide research is a genuinely broad and growing field, distinct from many other peptide application areas in that it encompasses both the front of the eye and the posterior segment, involves very different delivery challenges for each anatomical target, and spans conditions with different biological drivers. The research ecosystem reflects this diversity: some groups focus on structural problems like corneal collagen degradation and use collagen mimetic peptide chemistry; others focus on retinal cell survival and use neuroprotective fragment peptides; others focus on vascular disease and design VEGF-targeting or integrin-targeting compounds. The dominant study models are rodent models of specific diseases, including the rd10 mouse for retinitis pigmentosa, laser-induced choroidal neovascularization in rats for wet AMD, and desiccating stress models for dry eye disease. Researchers are also increasingly using human retinal organoids for testing compounds before animal work. Human organoid models are a methodological shift in this research area: because they use human tissue rather than mouse tissue, they help researchers identify which findings in rodent models are likely to translate to human biology and which reflect species-specific differences. The PEDF-derived 17-mer’s positive activity in human retinal organoids, complementing the H105A mouse model data, exemplifies how this approach is being used to strengthen confidence in preclinical findings before advancing to human trials. Research volume in this category has accelerated from 2020 through 2025, driven by several converging factors. The maturation of high-throughput peptide screening technologies allowed the TLR-inhibiting peptide discovery to screen 190,000 candidates efficiently. The emergence of self-assembling peptide chemistry enabled the AXT107 gel depot and peptide hydrogel approaches. The growing human observational database for GLP-1 receptor agonists has generated interest in direct ocular GLP-1 research. The field also benefits from the proximity of ocular research to the drug delivery engineering community, with cell-penetrating peptide and nanoformulation expertise increasingly being applied to make existing large-molecule drugs like aflibercept deliverable without injection.

Eye Health Clinical Pipeline and Trial Status

Eye health peptide research has produced more clinical trial activity than many other niche peptide application areas, primarily because dry eye disease and retinal vascular diseases represent large markets that attract substantial industry investment. ST-100 (vezocolmitide) holds the most advanced clinical position among specifically designed peptides for eye health, having completed both a Phase 2 trial (NCT05241470, 160 patients, with a positive primary endpoint result) and a Phase 3 trial. The Phase 3 results were reported as mixed, meaning that the strong Phase 2 signal did not fully replicate at the larger Phase 3 scale and with the longer follow-up required for regulatory purposes [4]. The ST-100 experience illustrates a pattern common in dry eye disease drug development: Phase 2 studies frequently show positive results that do not survive the more demanding conditions of Phase 3 evaluation, partly because placebo response rates in dry eye trials are high and partly because the condition is heterogeneous across patients. Regulatory approval was not confirmed in the available evidence. CG-P5 peptide eye drops are currently in Phase 1 safety evaluation (NCT06132035), focused on establishing tolerability in patients with an ophthalmic condition. A separate open-label Phase 1 equivalent study (NCT06787482) is evaluating low molecular weight peptides derived from fetal tissues, mesenchymal stem cells, and growth factors administered sublingually in patients with retinal dystrophies, AMD, and diabetic retinopathy. This study is tracking visual acuity, retinal thickness, vascular health markers, and VEGF levels over a 12-month period [16]. Both trials represent safety and feasibility assessments rather than efficacy evaluations. GLP-1 receptor agonists have not completed a randomized controlled trial with a primary eye health endpoint, though the weight of human observational data is substantial enough that multiple research groups have called for such trials to be conducted. ALG-1001 has been tested in human participants with documented posterior vitreous detachment effects, though the full trial details and phase status are not comprehensively documented in available sources. For all other peptides covered in this article, including PEDF-derived fragments, elamipretide for eye health, AXT107, bxyPenetratin, vasoactive intestinal peptide, peptide hydrogels, Fas-blocking peptides, host-defense peptides, TLR-inhibiting peptides, and collagen mimetic peptides for retinal tissue, no human clinical trial data exist specifically for eye health applications. These compounds remain entirely in preclinical research stages for this indication as of the evidence available to this article.

Eye Health Research Limitations and Evidence Gaps

Human Data Constraints

The most fundamental limitation in eye health peptide research is the overwhelming predominance of animal model data. Of the twelve peptide categories covered in this article, only two have generated human clinical data with a primary eye health focus: ST-100 in Phase 2 and Phase 3 dry eye trials, and GLP-1 receptor agonists in retrospective cohort analyses. ST-100’s Phase 3 mixed results introduce genuine uncertainty about whether the Phase 2 collagen repair findings translate to meaningful clinical benefit. GLP-1 receptor agonist data from human cohorts is consistently observational: patients were not randomly assigned to receive GLP-1 drugs for eye health reasons, and the populations studied had diabetes, making it difficult to separate the effects of better blood sugar control from direct ocular GLP-1 receptor effects. For the remaining peptides, including PEDF-derived fragments, elamipretide, AXT107, Fas-blocking peptides, and TLR-inhibiting peptides, the entire body of evidence rests on animal models and cell culture experiments. The average time from promising preclinical results to a completed Phase 3 trial is 10 to 15 years in ophthalmology, and the failure rate is high. Compounds that show dramatic effects in mouse models of retinal degeneration frequently show no effect in human trials, partly because mouse retinas differ significantly from human retinas in their organization and the cell types that dominate function.

Methodological Challenges

Several specific methodological weaknesses recur across eye health peptide research. Sample sizes in preclinical animal studies are consistently small, with six to eight animals per group cited explicitly in the peptide hydrogel research and typical of the field more broadly. These small sample sizes make individual studies prone to false-positive results, particularly when the same research group conducts the study and analyzes the outcome. Standard rodent models of retinal degeneration, including the rd10 mouse used in retinitis pigmentosa research, are caused by specific genetic mutations that differ from the genetics of most human RP patients. This raises questions about whether findings in this model predict responses in genetically diverse human populations. The delivery challenge is a methodological problem that extends beyond any individual peptide. Most peptides that protect photoreceptors in cell culture or in direct retinal injection experiments face substantial hurdles when delivered through the non-invasive routes that would make clinical use practical. The retina is separated from the tear film by layers of corneal tissue, aqueous humor, the lens, and vitreous fluid, each presenting a barrier to topical peptide delivery. Several compounds in this article, including PEDF-derived fragments and TLR-inhibiting peptides, have demonstrated retinal penetration from eye drops in mouse models. Mouse eyes are smaller than human eyes, however, and the geometry of drug distribution differs significantly between species.

Knowledge Gaps

Critical unanswered questions span the entire eye health peptide research landscape. For PEDF-derived peptides, the H105A and 17-mer findings are from 2025 publications and represent early-stage research that has not yet been replicated by independent groups. Long-term safety profiles for any topically applied peptide in the eye are essentially unknown: no compound has progressed far enough to generate long-term human safety data. The optimal dosing frequency, concentration, and formulation for retinal penetration from topical drops have not been established for most compounds. Head-to-head comparisons between different neuroprotective peptide approaches in the same animal model systems do not exist, making it impossible to assess relative potency or predict which approaches are most worth advancing to human trials. For GLP-1 receptor agonists, the critical question of whether any eye benefit requires reaching a specific therapeutic threshold in ocular tissues, or whether it operates through systemic blood sugar and inflammation reduction, remains unresolved. This question matters enormously for whether topical ocular GLP-1 formulations would have any advantage over systemic administration. For ST-100, the reasons for the discrepancy between Phase 2 and Phase 3 outcomes have not been published in sufficient detail in available sources to understand whether the Phase 2 result was an artifact of study design or whether a real but smaller effect was undetectable at Phase 3 scale. These gaps represent not just scientific unknowns but practical obstacles to making rational decisions about which peptides deserve the substantial investment required to advance them toward regulatory approval.

Regulatory and Research Classification

Current Status

FDA Classification: No peptide discussed in this article has received FDA approval for any eye health indication. GLP-1 receptor agonists including exenatide, lg, GLP1, and lixisenatide are FDA-approved for type 2 diabetes and, in some cases, for chronic weight management, but none for any ophthalmological indication. ST-100 (vezocolmitide) completed Phase 3 trials but regulatory approval has not been confirmed in available sources. Elamipretide has been studied in FDA-supervised trials for other indications (Barth syndrome, a rare mitochondrial cardiomyopathy) but not for eye health. PEDF-derived peptides, AXT107, Fas-blocking peptides, vasoactive intestinal peptide, and TLR-inhibiting peptides carry no FDA approval for any indication and are classified as investigational or research-use compounds in the United States. WADA Status: None of the peptides covered in this article currently appear on the WADA Prohibited List for eye health-specific applications. GLP-1 receptor agonists are not on the Prohibited List. Elamipretide, PEDF-derived peptides, vasoactive intestinal peptide, AXT107, and Fas-blocking peptides are not individually listed. Researchers and athletes in competitive sports contexts should verify the current WADA classification against the most recently published annual list, as classifications are updated each year. Research Compliance: Researchers using these compounds in laboratory settings require appropriate institutional oversight for any work involving human biological specimens, animal research protocols, or human participants. GLP-1 receptor agonists, when used outside their approved indications in formal human research, require investigational new drug (IND) authorization in the United States. All other peptides covered here are available from licensed research chemical suppliers for use in approved laboratory protocols operating under appropriate institutional review and regulatory frameworks.

Research Context

All peptides discussed in this article are subjects of ongoing scientific investigation conducted in laboratory and regulated clinical trial settings. They are not approved, validated, or recommended for self-administration outside of properly supervised research protocols. Their availability as research compounds is intended for use by qualified researchers in controlled experimental contexts, not for consumer or self-directed use in human eye health management.

Frequently Asked Questions About Eye Health Peptide Research

Are there any peptide eye drops currently available for treating eye disease?

No peptide eye drops are currently FDA-approved for treating any eye disease. Several peptide formulations are in clinical development or have been through trials: ST-100 (vezocolmitide) completed Phase 2 and Phase 3 trials for dry eye disease with mixed results, and CG-P5 peptide drops are currently in Phase 1 safety evaluation. PEDF-derived peptides have shown results in animal models and human tissue models as research tools, but no approved product exists. The compounds discussed in this article are research compounds, not approved treatments.

What eye conditions are peptides being studied for?

Peptide research for eye health covers a wide range of conditions. The most studied are age-related macular degeneration (both wet and dry forms), retinitis pigmentosa, dry eye disease, diabetic retinopathy and diabetic macular edema, glaucoma, and vitreomacular adhesion. Researchers are also exploring peptide approaches for ocular surface infections, age-related decline in vision function connected to mitochondrial damage in photoreceptors, and nonarteritic anterior ischemic optic neuropathy, a condition affecting the optic nerve.

Why is it so hard to get eye drops to reach the back of the eye?

Getting drugs to the retina through drops applied to the eye surface is one of the central challenges in ophthalmology and is not reliably achieved by conventional drugs. The retina sits behind layers of corneal tissue, lens, and a large volume of vitreous fluid, each of which clears or blocks most drugs before they arrive. Several peptide research programs specifically address this barrier: PEDF-derived peptide fragments are small enough to penetrate ocular tissues and were confirmed to reach the retina within 60 minutes of topical application in mouse models, while cell-penetrating peptides like TAT-μCL use a carrier mechanism to cross tissue barriers. Whether these approaches achieve clinically meaningful retinal concentrations in human eyes, which are larger and differently structured than mouse or rat eyes, is an open and important research question.

Do the GLP-1 drugs used for weight loss have any effect on eye health?

Human observational data suggest that GLP-1 receptor agonists are associated with several positive eye health outcomes in people with type 2 diabetes, including lower rates of dry eye disease, reduced risk of blindness, and possible protection against some forms of retinal disease. These findings come from retrospective studies rather than controlled experiments, so it is not possible to say definitively that the GLP-1 drugs caused these benefits as opposed to other differences between patients who take them and those who do not. A 2025 systematic review found no significant overall association with diabetic retinopathy development or worsening after careful analysis. No GLP-1 drug is approved or indicated for any eye health condition.

How far away are peptide treatments for conditions like macular degeneration or retinitis pigmentosa?

Most peptide approaches for retinal degeneration remain in early preclinical stages, meaning they have shown results in animal models or laboratory tissue experiments but have not yet been tested in human patients. The typical timeline from successful animal studies to a completed Phase 3 clinical trial in ophthalmology is ten to fifteen years, with a high failure rate at each stage. The PEDF-derived peptide findings published in 2025 represent promising early evidence. The most clinically advanced peptides for retinal diseases, such as GLP-1 receptor agonists, are still being characterized in human observational studies and have not completed a randomized trial with a retinal disease primary endpoint. Realistic timelines for any approved peptide treatment for macular degeneration or retinitis pigmentosa are difficult to estimate and likely measured in years to decades.

Are peptides being studied to replace anti-VEGF injections for macular degeneration?

Yes, reducing the burden of frequent anti-VEGF injections is an explicit goal of several peptide research programs. AXT107 forms a self-assembling gel depot inside the eye after injection, with the goal of extending the duration of anti-VEGF activity to reduce injection frequency. The bxyPenetratin delivery system aims to deliver aflibercept, one of the most used anti-VEGF drugs, to the retina through topical eye drops rather than injections. Peptide hydrogel formulations have shown anti-VEGF activity comparable to aflibercept over 14-day periods in rat models. None of these approaches have been tested in human patients yet, so it is not possible to say whether they will successfully replace injection-based treatment. Each approach faces significant development and regulatory hurdles before any clinical use would be possible. With shifting availability in the peptide industry, finding a Peptide Sciences alternative has become essential for ongoing studies.

References

1. NIH Research Matters. Peptide eye drops may help protect vision. National Institutes of Health. Source
2. Science Daily. AXT107 self-assembling peptide for retinal neovascularization (2017). ScienceDaily
3. JAMA Network Open / systematic review meta-analysis: GLP-1 receptor agonists and ocular outcomes in type 2 diabetes. Source
4. CRST Today: ST-100 (vezocolmitide) collagen mimetic peptide for dry eye disease; Phase 2 and Phase 3 results. Source
5. Molecular Vision: Vasoactive intestinal peptide, lacrimation, and dry eye disease mechanisms. Source
6. Advanced Science: bxyPenetratin cell-penetrating peptide conjugated to aflibercept for topical posterior segment delivery (2024). Wiley
7. PubMed: Peptide hydrogels reduced vascular leak in rat wet AMD models; comparable to aflibercept at 14 days. PubMed
8. PMC: Peptide hydrogel pro- and anti-angiogenic formulations in rat laser-induced choroidal neovascularization model. PubMed Central
9. PMC: Fas-blocking peptide 6R-FBP; retinal degeneration attenuation in rodent and rabbit models. PubMed Central
10. PMC: TAT-μCL cell-penetrating peptide; anterior and posterior ocular distribution after topical application in rats. PubMed Central
11. PMC: Elamipretide (SS31) in aged mice; photopic visual function preservation and reversal of acuity loss. PubMed Central
12. Retina Today: ALG-1001 integrin peptide therapy for vascular eye diseases (2013). Source
13. Retina Today: ALG-1001 integrin peptide therapy (2012). Source
14. Eye Health Academy: TLR-inhibiting peptide eye drops for dry AMD; preclinical findings (December 2024). Source
15. Drug Target Review: Non-invasive peptide eye drops for dry AMD; TLR pathway inhibition (December 2024). Source
16. ClinicalTrials.gov: NCT06787482, open-label peptide therapy study for retinal dystrophies, AMD, and diabetic retinopathy. Source